KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 8.19%.

  • Castle Biosciences' EBIT Margin fell 141100.0% to 8.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.17%, marking a year-over-year decrease of 98400.0%. This contributed to the annual value of 2.61% for FY2024, which is 335400.0% up from last year.
  • Castle Biosciences' EBIT Margin amounted to 8.19% in Q3 2025, which was down 141100.0% from 4.93% recorded in Q2 2025.
  • Castle Biosciences' 5-year EBIT Margin high stood at 5.92% for Q3 2024, and its period low was 91.3% during Q1 2022.
  • In the last 5 years, Castle Biosciences' EBIT Margin had a median value of 18.78% in 2021 and averaged 29.8%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -725200bps in 2022, then surged by 674900bps in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' EBIT Margin stood at 60.59% in 2021, then increased by 2bps to 59.55% in 2022, then skyrocketed by 86bps to 8.56% in 2023, then soared by 155bps to 4.69% in 2024, then tumbled by -275bps to 8.19% in 2025.
  • Its EBIT Margin stands at 8.19% for Q3 2025, versus 4.93% for Q2 2025 and 31.74% for Q1 2025.